A few days ago, the state organized the joint drug procurement office to issue the announcement of the national centralized drug procurement document (gy-yd2022-1), officially launched the seventh batch of national centralized drug procurement, and planned to open the bid on July 12. The document specifies the procurement type, agreed procurement quantity, procurement cycle, procurement agreement, declaration qualification, procurement execution instructions, etc. According to the documents, there are 61 varieties of drugs collected in this national drug collection, involving multiple treatment fields such as malignant tumor, cardiovascular disease and diabetes, including alfatinib oral normal release dosage form, iodopatol injection, metformin vigagliptin oral normal release dosage form, etc. In order to ensure the stable supply of drugs under centralized purchase, the national drug centralized purchase explored the mode of "standby supply enterprise". According to the results of drug selection, when the primary supplier cannot meet the market demand of the selected region, the standby supplier can obtain the identity of the primary supplier according to relevant procedures to ensure the drug supply. In terms of procurement implementation, the document specifies that in the procurement cycle, medical institutions will give priority to the products selected in the centralized drug purchase, and ensure the completion of the agreed procurement volume. On this basis, the remaining consumption of medical institutions can purchase other drugs with the same variety and appropriate price in accordance with the relevant provisions of the local centralized drug purchase management. It is reported that the disclosure of enterprise application information will be carried out in the morning of July 12, using offline disclosure or online live broadcast. (outlook new era)